文献速递肝病

格卡瑞韦/哌仑他韦治疗日本慢性基因2型丙型肝炎病毒感染患者的疗效与安全性

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
PubMed 文献 · Hepatology · 2017-11-24

CERTAIN-2是一项3期、开放标签、多中心研究,将136例无肝硬化基因2型丙型肝炎病毒感染的日本患者按2:1随机分配至8周格卡瑞韦/哌仑他韦组(A组)或12周索磷布韦+利巴韦林组(B组)。A组SVR12为88/90(97.8%),B组为43/46(93.5%),主要终点非劣效达成;CERTAIN-1中18例代偿期肝硬化患者接受12周格卡瑞韦/哌仑他韦,SVR12为100%(18/18)。

要点

  • 无肝硬化基因2型丙型肝炎患者8周格卡瑞韦/哌仑他韦SVR12达97.8%(88/90)。
  • 代偿期肝硬化基因2型患者12周格卡瑞韦/哌仑他韦SVR12达100%(18/18)。
  • 格卡瑞韦/哌仑他韦耐受性良好,无肝硬化患者每组各2例发生治疗期间严重不良事件。

核心结论

  • 格卡瑞韦/哌仑他韦在基因2型丙型肝炎病毒感染的日本患者中显示出高疗效和良好耐受性。

研究设计与样本

  • CERTAIN-2为3期、开放标签、多中心研究,纳入136例无肝硬化的基因2型丙型肝炎病毒感染的日本初治和干扰素±利巴韦林经治患者,按2:1随机分配至8周格卡瑞韦/哌仑他韦组(A组)或12周索磷布韦+利巴韦林组(B组)。
  • CERTAIN-1研究中,基因2型感染合并代偿期肝硬化的初治和干扰素±利巴韦林经治患者接受12周格卡瑞韦/哌仑他韦治疗。

主要发现

  • CERTAIN-2中,A组SVR12为88/90(97.8%),B组为43/46(93.5%)。
  • A组无患者发生病毒学失败,B组有2例发生病毒学失败。
  • CERTAIN-1中,代偿期肝硬化基因2型患者SVR12为100%(18/18)。
  • 无肝硬化患者中,A组和B组各有2例发生治疗期间严重不良事件;肝硬化患者中无患者发生治疗期间严重不良事件。

关键数值与推荐

  • 主要终点为意向治疗人群中格卡瑞韦/哌仑他韦相比索磷布韦+利巴韦林的SVR12非劣效性,该终点达成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once-daily, all oral, ribavirin (RBV)-free, direct-acting antiviral regimen, was evaluated for safety and efficacy in hepatitis C virus genotype 2 (GT2)-infected Japanese patients, including those with compensated cirrhosis. CERTAIN-2 is a phase 3, open-label, multicenter study assessing the safety and efficacy of G/P (300/120 mg) once daily in treatment-naive and interferon ± RBV treatment-experienced Japanese patients without cirrhosis but with GT2 infection. Patients were randomized 2:1 to receive 8 weeks of G/P (arm A) or 12 weeks of sofosbuvir (400 mg once daily) + RBV (600-1000 mg weight-based, twice daily) (arm B). The primary endpoint was noninferiority of G/P compared to sofosbuvir + RBV by assessing sustained virologic response at posttreatment week 12 (SVR12) among patients in the intent-to-treat population. SVR12 was also assessed in treatment-naive and interferon ± RBV treatment-experienced patients with GT2 infection and compensated cirrhosis who received G/P for 12 weeks in the CERTAIN-1 study. A total of 136 patients were enrolled in CERTAIN-2. SVR12 was achieved by 88/90 (97.8%) patients in arm A and 43/46 (93.5%) patients in arm B. No patient in arm A experienced virologic failure, while 2 did in arm B. The primary endpoint was achieved. In CERTAIN-1, 100% (18/18) of GT2-infected patients with compensated cirrhosis achieved SVR12. Treatment-emergent serious adverse events were experienced by 2 patients without cirrhosis in each arm and no patient with cirrhosis. Conclusion: The results demonstrate high efficacy and favorable tolerability of G/P in GT2-infected Japanese patients. (Hepatology 2018;67:505-513).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2017. PMID: 28865152. doi:10.1002/hep.29510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。